Expression of LDH and CEA in serum in the process of targeted therapy of lung adenocarcinoma and the association between them and prognosis

He,Guangsi; Jiang,Zonghui; Xue,Song; Sun,Xiaoyan; Wang,Weifei

doi:10.3892/ol.2019.10115

Expression of LDH and CEA in serum in the process of targeted therapy of lung adenocarcinoma and the association between them and prognosis

Authors:
- Guangsi He
- Zonghui Jiang
- Song Xue
- Xiaoyan Sun
- Weifei Wang
View Affiliations

Affiliations: The Second Department of Oncology, The First People's Hospital of Chuzhou, Chuzhou, Anhui 239000, P.R. China
Published online on: March 5, 2019 https://doi.org/10.3892/ol.2019.10115
Pages: 4550-4556

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Expression of lactate dehydrogenase (LDH) and carcinoembryonic antigen (CEA) in serum was investigated in the process of epidermal growth factor receptor‑tyrosine kinase inhibitor (EGFR‑TKI) targeting for treating lung adenocarcinoma and the association between LDH, CEA and prognosis of patients was evaluated. A retrospective analysis of 89 patients with lung adenocarcinoma admitted to The First People's Hospital of Chuzhou from January 2014 to February 2015 was performed. Fifty‑one patients who received resection were considered the operation group, while the other 38 patients received EGFR‑TKI targeted therapy and were considered the targeted group. Electrochemiluminescence and automatic biochemical analyzer were respectively used to detect the expression of CEA and LDH in serum. The therapeutic effective rates and the expression levels of LDH and CEA of the patients were compared. The patients in the targeted group were divided into LDH high‑expression group, LDH low‑expression group, CEA high‑expression group and CEA low‑expression group according to the median of the expression levels of LDH and CEA. The therapeutic effective rate in LDH high‑expression group (65.00%) was significantly lower than that in LDH low‑expression group (100.00%) (P=0.004). The therapeutic effective rate in CEA high‑expression group (64.71%) was significantly lower than that in CEA low‑expression group (95.24%) (P=0.016). The 3‑year overall mortality rate in LDH high‑expression group (47.37%) was significantly higher than that in LDH low‑expression group (11.11%) (P=0.034). The 3‑year overall mortality rate in CEA high‑expression group (56.25%) was significantly higher than that in CEA low‑expression group (4.76%) (P=0.020). The levels of CEA and LDH in serum were abnormally expressed in the process of the treatment of lung adenocarcinoma targeted by EGFR‑TKI, which had great significance for monitoring the efficacy and prognosis of the treatment of lung adenocarcinoma targeted by EGFR‑TKI.

View Figures

View References

1	Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al KEYNOTE-024 Investigators, : Pembrolizumab versus chemotherapy for PD-L1 - positive non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016. View Article : Google Scholar : PubMed/NCBI
2	Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet. 387:1540–1550. 2016. View Article : Google Scholar : PubMed/NCBI
3	Lou Y, Diao L, Cuentas ERP, Denning WL, Chen L, Fan YH, Byers LA, Wang J, Papadimitrakopoulou VA, Behrens C, et al: Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clin Cancer Res. 22:3630–3642. 2016. View Article : Google Scholar : PubMed/NCBI
4	Takada K, Okamoto T, Shoji F, Shimokawa M, Akamine T, Takamori S, Katsura M, Suzuki Y, Fujishita T, Toyokawa G, et al: Clinical significance of PD-L1 protein expression in surgically resected primary lung adenocarcinoma. J Thorac Oncol. 11:1879–1890. 2016. View Article : Google Scholar : PubMed/NCBI
5	Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, Goldberg S, et al: Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol. 34:123–129. 2016. View Article : Google Scholar : PubMed/NCBI
6	Schuler M, Wu YL, Hirsh V, O'Byrne K, Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V, et al: First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 11:380–390. 2016. View Article : Google Scholar : PubMed/NCBI
7	Ambrogio C, Gómez-López G, Falcone M, Vidal A, Nadal E, Crosetto N, Blasco RB, Fernández-Marcos PJ, Sánchez- Céspedes M, Ren X, et al: Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma. Nat Med. 22:270–277. 2016. View Article : Google Scholar : PubMed/NCBI
8	Martin JT, Durbin EB, Chen L, Gal T, Mahan A, Ferraris V and Zwischenberger J: Nodal upstaging during lung cancer resection is associated with surgical approach. Ann Thorac Surg. 101:238–244; discussion 44–45. 2016. View Article : Google Scholar : PubMed/NCBI
9	Kwon Y: Mechanism-based management for mucositis: Option for treating side effects without compromising the efficacy of cancer therapy. OncoTargets Ther. 9:2007–2016. 2016. View Article : Google Scholar
10	Chen QY, Jiao DM, Wang J, Hu H, Tang X, Chen J, Mou H and Lu W: miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET. Oncotarget. 7:24510–24526. 2016.PubMed/NCBI
11	Zeng Z, Bo H, Gong Z, Lian Y, Li X, Li X, Zhang W, Deng H, Zhou M, Peng S, et al: AFAP1-AS1, a long noncoding RNA upregulated in lung cancer and promotes invasion and metastasis. Tumour Biol. 37:729–737. 2016. View Article : Google Scholar : PubMed/NCBI
12	Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW, Hilton JF, et al: Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov. 6:740–753. 2016. View Article : Google Scholar : PubMed/NCBI
13	Lou TF, Sethuraman D, Dospoy P, Srivastva P, Kim HS, Kim J, Ma X, Chen PH, Huffman KE, Frink RE, et al: Cancer-specific production of N-acetylaspartate via NAT8L overexpression in non-small cell lung cancer and its potential as a circulating biomarker. Cancer Prev Res (Phila). 9:43–52. 2016. View Article : Google Scholar : PubMed/NCBI
14	Wu SG, Liu YN, Tsai MF, Chang YL, Yu CJ, Yang PC, Yang JC, Wen YF and Shih JY: The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget. 7:12404–12413. 2016.PubMed/NCBI
15	Ahn MJ, Sun JM, Lee SH, Ahn JS and Park K: EGFR TKI combination with immunotherapy in non-small cell lung cancer. Expert Opin Drug Saf. 16:465–469. 2017. View Article : Google Scholar : PubMed/NCBI
16	Zheng D, Ye X, Zhang MZ, Sun Y, Wang JY, Ni J, Zhang HP, Zhang L, Luo J, Zhang J, et al: Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Sci Rep. 6:209132016. View Article : Google Scholar : PubMed/NCBI
17	Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, Huynh TG, Zhao L, Fulton L, Schultz KR, et al: EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer (NSCLC): A retrospective analysis. Clin Cancer Res. 22:4585–4593. 2016. View Article : Google Scholar : PubMed/NCBI
18	Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Ouaret D, Bodmer W, Lehmann S, Hofer T, Hosse RJ, et al: A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumor. Clin Cancer Res. 22:3286–3297. 2016. View Article : Google Scholar : PubMed/NCBI
19	Valvona CJ, Fillmore HL, Nunn PB and Pilkington GJ: The regulation and function of lactate dehydrogenase A: Therapeutic potential in brain tumor. Brain Pathol. 26:3–17. 2016. View Article : Google Scholar : PubMed/NCBI
20	Shiono S and Yanagawa N: Spread through air spaces is a predictive factor of recurrence and a prognostic factor in stage I lung adenocarcinoma. Interact Cardiovasc Thorac Surg. 23:567–572. 2016. View Article : Google Scholar : PubMed/NCBI
21	Minguet J, Smith KH and Bramlage P: Targeted therapies for treatment of non-small cell lung cancer - recent advances and future perspectives. Int J Cancer. 138:2549–2561. 2016. View Article : Google Scholar : PubMed/NCBI
22	Cha YJ, Kim HR, Lee CY, Cho BC and Shim HS: Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. Lung Cancer. 97:73–80. 2016. View Article : Google Scholar : PubMed/NCBI
23	Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC8 Lee KH, Lu S, et al: Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial. Lancet Oncol. 17:577–589. 2016. View Article : Google Scholar : PubMed/NCBI
24	Yang JCH, Sequist LV, Zhou C, Schuler M, Geater SL, Mok T, Hu CP, Yamamoto N, Feng J, O'Byrne K, et al: Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: Post hoc analyses of the randomized LUX-Lung 3 and 6 trials. Ann Oncol. 27:2103–2110. 2016. View Article : Google Scholar : PubMed/NCBI
25	Zhou M, Snedecor BR, Ng CKD and Shen A: Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase. US Patent 9,487,809, Filed November 28 2012. November 8–2016.
26	Mohammad GH, Olde Damink SW, Malago M, Dhar DK and Pereira SP: Pyruvate kinase M2 and lactate dehydrogenase A are overexpressed in pancreatic cancer and correlate with poor outcome. PLoS One. 11:e01516352016. View Article : Google Scholar : PubMed/NCBI
27	Sørensen CG, Karlsson WK, Pommergaard HC, Burcharth J and Rosenberg J: The diagnostic accuracy of carcinoembryonic antigen to detect colorectal cancer recurrence - A systematic review. Int J Surg. 25:134–144. 2016. View Article : Google Scholar : PubMed/NCBI
28	Koukourakis MI, Kakouratos C, Kalamida D, Bampali Z, Mavropoulou S, Sivridis E and Giatromanolaki A: Hypoxia-inducible proteins HIF1α and lactate dehydrogenase LDH5, key markers of anaerobic metabolism, relate with stem cell markers and poor post-radiotherapy outcome in bladder cancer. Int J Radiat Biol. 92:353–363. 2016. View Article : Google Scholar : PubMed/NCBI